<DOC>
	<DOCNO>NCT00606099</DOCNO>
	<brief_summary>This study design evaluate efficacy safety telbivudine 600mg versus adefovir dipivoxil 10mg patient compensate chronic hepatitis B .</brief_summary>
	<brief_title>Efficacy Safety Telbivudine Patients With Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>Male female , least 18 year age . Patients compensate chronic hepatitis B currently receive adefovir 10mg daily . Patients must receive adefovir 10mg daily least 48 week continuously suboptimal response adefovir therapy ( â‰¥4log10 copy HBV DNA/mL ) . Patient willing comply study requirement . Patient willing able provide write informed consent . Pregnant nursing ( lactate ) woman . All woman must negative pregnancy test screen visit . Female patient reproductive potential unwilling use double barrier method contraception ( condom plus spermicide diaphragm plus spermicide ) . Patient coinfected hepatitis C virus HIV . Patient previously take lamivudine . Patient currently abuse illicit drug alcohol . Patient use investigational drug last 30 day . Patient enrol plan enroll clinical study involve investigational drug . Patient history pancreatitis , hepatic decompsensation , Hepatocellular Carcinoma , history hypersensitivity telbivudine adfovir . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Adults</keyword>
	<keyword>compensate chronic hepatitis B</keyword>
	<keyword>telbivudin</keyword>
	<keyword>aedevofir dipivoxil</keyword>
</DOC>